

Lawrence Jin, Don Kenkel\*, Feng Liu and Hua Wang

## Retrospective and Prospective Benefit-Cost Analyses of U.S. Anti-Smoking Policies<sup>1</sup>

**Abstract:** Regulatory policies designed to improve societal welfare by “nudging” consumers to make better choices are increasingly popular. The application of benefit-cost analysis (BCA) to this sort of regulation confronts difficult theoretical and applied issues. In this analysis we contribute a worked example of behavioral BCA of U.S. anti-smoking policies. Our conceptual framework extends the standard market-based approach to BCA to allow for individual failures to make lifetime-utility-maximizing choices of cigarette consumption. We discuss how our market-based approach compares to the health benefits approach and the “consumer surplus offset” controversy in recent BCAs of several health-related regulations. We use a dynamic population model to make counterfactual simulations of smoking prevalence rates and cigarette demand over time. In our retrospective BCA the simulation results imply that the overall impact of anti-smoking policies from 1964 to 2010 is to reduce the total cigarette consumption by 28%. At a discount rate of 3% the 1964–present value of the consumer benefits from anti-smoking policies through 2010 is estimated to be \$573 billion (\$2010). Although we are unable to develop a hard estimate of the policies’ costs, we discuss evidence that suggests the consumer benefits substantially outweigh the costs. We then turn to a prospective BCA of future anti-smoking Food and Drug Administration (FDA) regulations. At a discount rate of 3%, the 2010–present value of the consumer benefits 30 years into the future from a simulated FDA tobacco regulation is estimated to be \$100 billion. However, the nature of potential FDA tobacco regulations suggests that they might impose additional costs on consumers that make it less clear that the net benefits of the regulations will be positive.

**Keywords:** addiction; behavioral economics; smoking.

**JEL classifications:** D61; I18.

<sup>1</sup> We thank Glenn Blomquist and an anonymous referee for very useful comments. We also thank the following people for their insights and stimulating discussions of issues in this analysis: Frank Chaloupka, James Choi, David Cutler, Sherry Glied, James K. Hammitt, Amber Jessup, Joseph Newhouse, Lisa A. Robinson, Martha Starr, and Kenneth Warner. The findings and conclusions of this paper are solely those of the authors.

**Lawrence Jin:** Cornell University, USA, e-mail: ljj9@cornell.edu

**\*Corresponding author: Don Kenkel,** Cornell University & NBER, USA,  
e-mail: dsk10@cornell.edu

**Feng Liu:** Shanghai University of Finance and Economics, China

**Hua Wang:** Cornell University, USA

# 1 Introduction

Regulatory policies designed to improve societal welfare by “nudging” consumers to make better choices are increasingly popular. Energy-efficiency labels or standards for light bulbs, appliances, and motor vehicles encourage or require consumers to choose more energy-efficient products to lower their energy costs. The 2010 Patient Protection and Affordable Care Act requires restaurants to post calorie information to encourage healthier food choices. The 2009 Family Smoking Prevention and Tobacco Control Act requires graphic warning labels on cigarette packages to discourage youth from starting to smoke and to encourage current smokers to cut down or quit. As part of the Regulatory Impact Analysis (RIA) process required by Executive Orders 12866 and 13563, federal agencies have completed benefit-cost analyses (BCAs) of each of these regulations.<sup>2</sup> The BCAs estimate that these regulations create substantial benefits for consumers by helping them make better choices.

The idea that consumers can be nudged into choices that make them better off is an important insight from behavioral economics (Thaler & Sunstein, 2009). However, the application of BCA to this sort of regulation confronts difficult theoretical and applied issues. The doctrine of revealed preference is fundamental to BCA, yet the case for nudge regulations rests on evidence that in some situations people’s observed consumption choices are not reliable indicators of their underlying preferences. Bernheim and Rangel (2007, 2009) extend the standard choice-theoretic approach to provide a theoretical foundation for behavioral welfare economics. Robinson and Hammitt (2011) discuss principles and standards for incorporating behavioral economics insights into applied BCA. Behavioral BCA promises to be controversial: for example Gayer and Viscusi (2013) criticize recent BCAs of energy-efficient standards; and as will be discussed in more detail below a number of comments criticize recent BCAs of Food and Drug Administration (FDA) tobacco regulations. Although the controversies will probably not be easily resolved, we believe that worked examples for important policies will help further develop the methods of behavioral BCA.

In this analysis we contribute to the behavioral BCA of U.S. anti-smoking policies. Warner (2007, p. S314) calls the drop in smoking since the 1950s “the developed world’s greatest public health achievement in the past half-century.” Our retrospective BCA of anti-smoking policies estimates the dollar value of the benefits to consumers that flow from this achievement. Yet Warner (2007, p. S314)

---

<sup>2</sup> See Gayer and Viscusi (2013) for discussion and references to a set of RIAs of energy-efficiency standards, the FDA (2014b) for the RIA of menu calorie labeling, and the FDA (2010, 2011) for RIAs of cigarette graphic warning labels.

is also quick to point out that the “the glass remains half empty.” Almost 20% of U.S. adults are current smokers (King, Dube & Tynan, 2012). Smoking is estimated to cause more than 400,000 deaths each year and remains the leading preventable cause of death (Mokdad, Marks, Stroup & Gerberding, 2004). The 2009 Family Smoking Prevention and Tobacco Control Act gives the FDA broad authority to regulate the tobacco industry to promote public health. Our prospective BCA estimates potential benefits from future FDA tobacco regulations.

As described in more detail in Section 2, our conceptual framework extends the standard market-based approach to BCA to allow for individual failures to make lifetime-utility-maximizing choices of cigarette consumption. The conceptual framework uses Ashley, Nardinelli and Lavaty’s (2014) extension of the approach developed in the Australian Productivity Commission (2010) BCA of legalized gambling and the smoking study by Weimer, Vining and Thomas (2009). In contrast to Ashley et al. and other previous studies, our empirical work takes a reduced-form approach that relies on high-level parameters: the price-elasticity of cigarette demand; and estimates of the impact of individual failures on the market demand for cigarettes.<sup>3</sup> In Section 2 we also discuss how our market-based approach compares to the health benefits approach and the “consumer surplus offset” controversy in several recent BCAs of health-related regulations.

In the remaining sections of the paper we conduct a retrospective BCA of U.S. anti-smoking policies from 1964 to 2010 and a prospective BCA of future anti-smoking FDA regulations. Section 3 describes the dynamic population model and data sources we use to make counterfactual simulations of smoking prevalence rates and cigarette demand over time. Section 3 also reports our estimates of the impact of anti-smoking policies. Based on the simulation results we estimate that the overall impact of anti-smoking policies from 1964 to 2010 is to reduce the total cigarette consumption by 28%.

Section 4 reports our retrospective BCA of past anti-smoking policies. To preview a key result: at a discount rate of 3% the 1964–present value of the consumer benefits from U.S. anti-smoking policies through 2010 is estimated to be \$573 billion (all reported benefits and costs are adjusted for inflation and expressed in real \$2010). To provide some context: the 1964–present value of the benefits from anti-smoking policies of \$573 billion is about 12% of the 1964 gross domestic product, and is somewhat larger than federal defense spending in 1964 (\$460 billion) and much larger than federal spending on health care in 1964 (\$12 billion).<sup>4</sup>

<sup>3</sup> Chetty (2009), Mullainathan et al. (2012) review the theory and practice of reduced-form versus structural approaches to standard and behavioral welfare economics.

<sup>4</sup> Authors’ calculations from Bureau of Economic Analysis (2015, Table of “Current-dollar and ‘real’ GDP”) and U.S. Government Publishing Office (2015, Table 3.2).

We are unable to develop a hard estimate of the costs of anti-smoking policies from 1964 to 2010. However, we discuss evidence that suggests the consumer benefits substantially outweigh the costs.

Section 5 reports our prospective BCA of future anti-smoking FDA regulations. To preview another key result: at a discount rate of 3% the 2010–present value of the consumer benefits 30 years into the future from a simulated FDA tobacco regulation is estimated to be \$100 billion. However, the nature of potential FDA tobacco regulations suggests that they might impose additional costs on consumers that make it less clear that the net benefits of the regulations will be positive. Section 6 is a concluding discussion.

## 2 Conceptual approach to BCA of anti-smoking policies

### 2.1 Market-based approach to BCA

Our BCA focuses on anti-smoking policies that help correct individual failures in making utility-maximizing choices about cigarette consumption. The benefits to the consumer are measured by the compensating variation (CV) in income for the anti-smoking policy under consideration. Assume the consumer's lifetime utility is given by  $U = U(A, G, H, Y)$ , where  $A$  is the quantity of cigarettes consumed,  $G$  is the quality of cigarettes consumed,  $H$  is health, and  $Y$  is a composite commodity with its price normalized to one. Letting the subscript 0 indicate consumption choices made in the absence of the policy and  $\Delta$  indicate the policy-induced changes, the CV for the policy is defined to satisfy the equation:

$$U(A_0, G_0, H_0, Y_0) = U(A_0 + \Delta A, G_0 + \Delta G, H_0 + \Delta H, Y_0 + \Delta Y + CV). \quad (1)$$

In equation (1) the utility function that defines the CV is in terms of experienced utility, which may differ from decision utility (Kahneman, Wakker & Sarin, 1997). In particular, the consumer's experienced lifetime utility depends on the true health consequences of smoking even if these consequences are not fully incorporated into her decisions. The typical anti-smoking policy reduces the quantity ( $\Delta A < 0$ ) or quality ( $\Delta G < 0$ ) of cigarettes consumed over the lifetime. As a result, the consumer's lifetime health improves ( $\Delta H > 0$ ). Because she spends less money on cigarettes her consumption of the composite commodity increases ( $\Delta Y > 0$ ).<sup>5</sup> If

<sup>5</sup> The policy could also affect income available to spend on the composite commodity by changing the consumer's lifetime spending on health care. A health-improving policy can either decrease or increase

experienced utility and decision utility are the same so that the consumer's choices  $A_0$  and  $G_0$  maximize her experienced lifetime utility, the changes induced by the policy make her worse off. The utility losses from  $\Delta A$  and  $\Delta G$  outweigh the utility gains from  $\Delta H$  and  $\Delta Y$ . The policy can make the consumer better off when experienced utility and decision utility are different so the consumer's original choices fail to maximize lifetime utility. In this case the utility gains from  $\Delta H$  and  $\Delta Y$  outweigh the utility losses from  $\Delta A$  and  $\Delta G$ . Lifetime cigarette consumption might fail to maximize lifetime utility due to the consumer's poor information about the health consequences of smoking, other decision-making errors that lead to imperfect optimization, or bounded self-control.

The CV places a dollar value on the net utility gain (or loss) from the anti-smoking policy. The definition of the CV in equation (1) does not require any assumptions about the consumer's ability to make lifetime-utility-maximizing choices of  $A$ ,  $G$ ,  $H$  and  $Y$ . Adding the standard assumptions about rationality implies that the CV can be measured as an area of consumer surplus under the consumer demand curve (Deaton & Muellbauer, 1980, pp. 184–189). Following the Australian Productivity Commission (2010), Weimer et al. (2009), Ashley et al. (2014) we assume that the observed market demand curve for cigarettes might not reflect fully optimizing decisions. Instead, we measure the area of consumer surplus that corresponds to the CV with respect to a hypothetical demand curve “which summarizes utility-maximizing decisions by consumers who are aware of all health costs and have fully incorporated them into consumption decisions” (Ashley et al., 2014, p. 2). We tailor the Ashley et al. conceptual framework to our retrospective and prospective BCA as follows.

For the retrospective BCA our framework needs to allow for a situation where initially poorly informed consumers become much better informed over time. Our retrospective study period starts in 1964. This is only about a decade after the scientific research establishing the link between smoking and lung cancer began to receive major media attention and the new information was still diffusing to the public (Viscusi, 1992). In a Gallup Poll conducted in 1960 only about half of the respondents agreed that smoking was one of the causes of lung cancer (Gallup, 1960). As will be discussed in more detail below in Section 3, the 1964 Surgeon General's Report is widely seen as a landmark publication that directly provided information and indirectly helped launch other initiatives to provide information about the health consequences of smoking. By the late 1990s general population surveys found that virtually all U.S. consumers were aware of the links

---

lifetime health care spending depending on its impact on per-period spending relative to its impact to lengthen the lifetime. The empirical evidence on the impact of cigarette smoking on lifetime health care spending is mixed.

between cigarette smoking and the risks of lung cancer, heart disease and emphysema (Kenkel & Chen, 2000). A series of studies in the 1990s and 2000s provide evidence that most people in the US, including most smokers, overestimate the health risks of cigarette smoking.<sup>6</sup> While this evidence has attracted some controversy, it is not controversial to conclude that by the end of our study period in 2010 consumer information about the major health risks of smoking is very widespread.<sup>7</sup>

For both our retrospective and prospective analyses it is also important that our framework allows for the possibility that consumers might make other decision-making errors that lead to imperfect optimization, or have bounded self-control. Psychological and behavioral economics research document decision-making errors across a range of domains (DellaVigna, 2009). However, Robinson and Hammitt (2011, p. 2) point out that: "Much of the research involves small-scale laboratory experiments and needs to be supplemented by additional fieldwork to explore the real-world importance of the findings." The real-world importance for the cigarette market is controversial. Survey evidence shows that many more smokers state that they intend to quit in the future than actually do so. This has been interpreted as evidence of the time-inconsistency predicted by behavioral economic models with hyperbolic discounting. However, statements about quit intentions can also be viewed with the same general skepticism economists view simple statements about preferences.<sup>8</sup> Econometric research into the market for cigarettes has not been able to distinguish rational addiction from a forward-looking model with quasi-hyperbolic discounting and time-inconsistency.<sup>9</sup> Studies of self-commitment devices provide another source of evidence that some smokers

---

**6** See for example Viscusi (1990, 1991, 1992), Khwaja, Silverman, Sloan and Wang (2009), Sloan and Platt (2011).

**7** In a recent survey Sloan and Wang (2008) conclude that: "The economic literature lends no empirical support to the view that mature adults smoke because they underestimate the probability of harm to health from smoking."

**8** Viscusi (1992, p. 120) provides other examples of inconsistencies between simple statements about preferences and actual behavior: "Almost half of the residents of Los Angeles indicate a desire to move out of the city, but do not do so. Almost one third of all blue-collar workers would like to leave their jobs but do not." He suggests that this type of survey evidence should be interpreted as showing some dissatisfaction with the situation in question. But it does not necessarily follow from the survey evidence that choices to smoke, live in Los Angeles or work in a blue-collar job fail to maximize lifetime utility. The simple statements in these surveys are different than the modern methods of preference elicitation used in contingent valuation surveys. Contingent valuation surveys are carefully designed to yield responses that will match real-world behavior, but even so the method remains controversial (Kling, Phaneuf & Zhao, 2012; Carson, 2012; Hausman, 2012). There are a few contingent valuation surveys about smoking including: Busch et al. (2004), Hammar and Johansson-Stenman (2004), Weimer et al. (2009).

**9** Gruber and Koszegi (2001) compare an empirical rational addiction model to an alternative model with time-inconsistent addiction and conclude that "we are unable to empirically distinguish the two with our data." (p. 1263).

recognize that they face time-inconsistency problems (Khawaja, Silverman & Sloan, 2007; Gine, Karlan & Zinman, 2010). The available research provides evidence that the observed demand for cigarettes reflects individual failures to make lifetime-utility-maximizing decisions, but there is less evidence on the extent and precise nature of the individual failures.

To capture the issues discussed above, our conceptual framework assumes that initially consumers fail to make lifetime-utility-maximizing choices about cigarette consumption, but these failures are corrected over time with the help of anti-smoking policies. We take a reduced-form approach and do not specify the precise nature of the individual failures. Instead we assume that the individual failures stem from some combination of poor information about the health consequences of smoking, other decision-making errors that lead to imperfect optimization, and bounded self-control.


Figure 1 is a graphical illustration of the framework. The cigarette consumption observed in year  $t$  is  $A_{Ot}$  at the intersection of the market price  $P_t$  and the observed demand curve  $D_{Ot}$ . The counterfactual cigarette consumption that would have been observed in year  $t$  in the absence of any anti-smoking policies is  $A_{CFt}$  at the intersection of  $P_t$  and the counterfactual demand curve  $D_{CFt}$ .  $A_{CFt}$  is also the starting point of the retrospective BCA, so the horizontal distance  $A_{CFt} - A_{Ot}$  shows the impact of anti-smoking policies as of year  $t$ . The rational utility-maximizing consumption is  $A_{Rt}$  at the intersection of  $P_t$  and the rational demand curve  $D_{Rt} | A_{t-1}$ . The notation  $D_{Rt} | A_{t-1}$  reflects that because cigarettes are addictive the rational level of demand at time  $t$  depends on the addictive stock determined by past consumption at time  $t - 1$ .<sup>10</sup>

The vertical distances between  $D_{CFt}$  and  $D_{Ot}$  or  $D_{Rt} | A_{t-1}$  show the dollar values of the individual failures to maximize utility. Individuals make errors and only internalize a fraction of the value of the health consequences of their cigarette consumption.<sup>11</sup> Following what is becoming conventional usage we will call the uninternalized portion of the health consequences the “marginal internality” (Mullainathan, Schwartzstein & Congdon, 2012).

Because Figure 1 can be used to show the welfare consequences of anti-smoking policies that partly or completely correct individual failures it provides the framework for our retrospective and prospective BCAs. The framework can be viewed as a modification of Harberger’s (1971) first basic postulate for BCA, where

<sup>10</sup> This assumes the addictive stock completely depreciates in one period. More generally the addictive stock is a weighted average of consumption in all past periods.

<sup>11</sup> The fraction could be greater than 1 if consumers think an unhealthy good is even riskier than it actually is. The studies cited above in footnote 5 suggest some consumers make this type of mistake about cigarettes. The fraction could be less than zero if consumers think an unhealthy good is actually healthy, but this seems very unlikely for cigarettes.



**Figure 1** Conceptual framework.

the value of the marginal unit to demanders is given by the height of the rational demand curve  $D_{Rt} | A_{t-1}$ . In our retrospective BCA, anti-smoking policies as of year  $t$  reduce cigarette consumption from  $A_{Cf_t}$  to  $A_{O_t}$ . Consumer spending on cigarettes falls by an amount given by the area  $J + K + L$ . The rational valuation of the foregone consumption is given by area  $L$  under  $D_{Rt} | A_{t-1}$ , yielding net consumer benefits given by area  $J + K$ . In our prospective BCA we consider a hypothetical FDA regulation that further reduces cigarette consumption from  $A_{O_t}$  to  $A_{R_t}$ . By the same reasoning this reduction in consumption yields benefits given by the triangular area  $G$ .

Another way to view the framework is in terms of the rule: the CV for a policy that changes cigarette consumption by  $\Delta A$  is given by  $\Delta A$  multiplied by the average value of the marginal internality. This rule is consistent with the general expression for the marginal welfare gain with behavioral agents in Mullainathan et al. (2012, equation 6, p. 521). In our retrospective BCA, because  $A_{Cf_t} - A_{O_t}$  shows the impact of anti-smoking policies as of year  $t$ , the year  $t$  value of those policies is  $A_{Cf_t} - A_{O_t}$  times the average of the vertical distance between  $D_{Cf_t}$  and  $D_{Rt} | A_{t-1}$  (the marginal internality at  $A_{Cf_t}$ ) and the vertical distance between  $D_{O_t}$  and  $D_{Rt} | A_{t-1}$  (the marginal internality at  $A_{O_t}$ ). This again corresponds to the sum of the area  $J + K$ . In the case drawn in Figure 1 the policy benefits (area  $J + K$ ) are necessarily smaller than the reduction in consumer spending on cigarettes



(area  $J + K + L$ ). However, this need not hold because depending on the size of the marginal internality the rational demand curve  $D_{Rt} | A_{t-1}$  can be below the horizontal axis. This occurs if at  $A_{Ot}$  given rational demand the value of the marginal cigarette is negative because of the health consequences.

A policy that completely corrects the individual failures would change cigarette consumption by  $A_{CFt} - A_{Rt}$ . The value of such a policy is  $A_{CFt} - A_{Rt}$  times the average of the vertical distance between  $D_{CFt}$  and  $D_{Rt} | A_{t-1}$  (the marginal internality at  $A_{CFt}$ ) and 0 (the marginal internality at  $A_{Rt}$ ), corresponding to the familiar triangular area  $G + J + K$ .

Viewed from a static perspective, Figure 1 shows that the welfare gains from future anti-smoking policies diminish when past policies have already partly corrected the individual failures to maximize. For example, the area  $J + K$  of consumer benefits from reducing  $A_{CFt}$  to  $A_{Ot}$  is much larger than the area  $G$  of consumer benefits from reducing  $A_{Ot}$  to  $A_{Rt}$ . This pattern is because the size of the welfare gain depends on the size of the marginal internality, which is much larger at  $A_{CFt}$  than at  $A_{Ot}$ .

However, BCA of anti-smoking policies involves important dynamics because addiction creates linkages between the demand curves across time. Consider a policy at time  $t$  that helps consumers internalize more of the health consequences of smoking and thus causes the demand curve to shift from  $D_{CFt}$  to  $D_{Ot}$ . While the area  $J + K$  measures the policy benefits at time  $t$ , the reduced consumption level  $A_{Ot}$  means that consumers at time  $t + 1$  have a lower addictive stock. In the time  $t + 1$  version of Figure 1 both the observed demand curve  $D_{Ot+1}$  and the rational demand curve  $D_{Rt+1} | A_t$  shift inwards toward the origin reflecting the lower addictive stock. In a way, the rational utility-maximizing level of consumption  $A_{Rt+1}$  is a moving target: the reduced consumption at time  $t$  reduces how much rational consumers would choose to smoke at time  $t + 1$ .

Importantly, the dynamics of cigarette demand reflect the utility costs of withdrawing from cigarette addiction. For a given addictive stock, much of the rational demand for cigarettes might simply be to avoid withdrawal costs. Hughes (2007) reviews research on the effects of abstinence from tobacco and concludes (p. 315) that: "Anger, anxiety, depression, difficulty concentrating, impatience, insomnia, and restlessness are valid withdrawal symptoms that peak within the first week and last 2–4 weeks." Hughes also mentions that other research reviews provide evidence for additional withdrawal symptoms that include craving, decreased heart rate, electroencephalographic changes, hunger and weight gain, impaired cognitive performance, increased monoamine oxidase levels, and changes in medication levels. Even with the aid of pharmaceutical smoking cessation products most quit attempts are unsuccessful, which provides more evidence that the withdrawal costs from

cigarette addiction are high and also suggests that withdrawal is difficult to treat. Most smokers require multiple quit attempts before they succeed: in a typical example it might take a smoker roughly three years to quit, during which time they attempt to quit 6–11 times with the average episode lasting 1.5 weeks (Hughes, Keely & Naud, 2004). This implies that successful quitters spend on average 12 weeks of withdrawal symptoms during their serious attempts to quit. Rational cigarette demand might be mainly driven by the value of cigarettes as a means to reduce the utility losses from withdrawal.

When considering the rational demand for cigarettes at time  $t$ , the rationality of smokers' past decisions is irrelevant. Many smokers' past decisions might have been irrational. Nevertheless, even these smokers' current and forward-looking decisions about how much to smoke and whether to quit can be rational. A typical example might be someone who made a time-inconsistent decision to initiate smoking as an adolescent and became addicted. The past mistake to become addicted is a sunk cost. Given their current addictive stock, the question of rationality depends on whether they are making fully informed time-consistent decisions about continuing to smoke. Put differently, currently rational smokers are not necessarily "happy addicts" – they may very much regret their earlier time-inconsistent decision to start smoking. They can be currently rational in the sense that their current decisions to continue smoking are time consistent and do not impose internalities on their future selves.

Our retrospective and prospective BCAs of anti-smoking policies implement the framework summarized in Figure 1. We use a dynamic population model to compare observed cigarette consumption over time to consumption under simulated counterfactuals. To simulate rational consumption over time, we use the smoking rates of a group of consumers whose behavior tends to approximate fully informed rational decision making. The dynamic population model simulations build in the linkages between the demand curves across time. By combining the simulation results with a consensus price-elasticity estimate we construct a series of demand curves  $D_{CF}$ ,  $D_O$  and  $D_R | A_{t-1}$  over time and use them to calculate the areas  $J + K$  and  $G$ .

## 2.2 The health benefits approach and consumer surplus offset

In contrast to the market-based approach summarized in Figure 1, several recent BCAs of health-related regulations use what we term the health benefits approach. Although the approaches are not necessarily inconsistent and indeed Figure 1 can illustrate both, the approaches implicitly frame the policy problem quite differently.

The market-based approach frames the problem as: we use BCA to determine if the policy leads to a market outcome that is closer to the socially optimal quantity. In a general version of Figure 1 the socially optimal quantity maximizes the sum of consumer and producer surplus, after taking into account market failures like externalities and, in a behavioral BCA, individual failures like internalities.<sup>12</sup> The public health missions of federal agencies like the FDA make this framing of the problem seem foreign. From a public health perspective, the optimal level of cigarette consumption is obviously zero. Consistent with the agencies' public health missions, the health benefits approach frames the problem as: we use BCA to measure the value of the policy-induced health gains and to see if the health benefits justify the costs. As reflected in Harberger's (1971) first basic postulate, consumer surplus is at the heart of the market-based approach to BCA. In contrast, in the health benefits approach consumer surplus is framed as a possible cost that offsets some of the health benefits. This frame is not necessarily inconsistent with OMB's guidance for RIAs. After discussing approaches for valuing policy benefits, Office of Management and the Budget (2011, p. 10) advises but does not require that agencies should include gains or losses in consumer or producer surplus "where relevant."<sup>13</sup>

As we just mentioned, Figure 1 can be used to illustrate the health benefits approach to BCA. Consider an anti-smoking policy that corrects all individual failures and reduces cigarette consumption by  $A_{CF_t} - A_{R_t}$ . The health benefits approach focuses on the health gains, as measured for example by quality-adjusted life years (QALYs), predicted to flow from the reduction in smoking. Using standard estimates of the dollar value of a QALY yields an estimate of the dollar value of the policy-induced health gains. Ashley et al. (2014) refer to this as the gross health benefits of the anti-smoking policy. Because the vertical distance between  $D_{CF_t}$  and  $D_R | A_{t-1}$  is by definition the dollar value of the health consequences of smoking, the gross health benefits of a policy that decreases cigarette consumption by  $A_{CF_t} - A_{R_t}$  is given by the area  $E + F + I + G + J + K$ .

The health benefits approach to BCA calculates the anti-smoking policy's gross health benefits and then calculates how much of the benefits are offset by lost consumer surplus from the reduction in cigarette consumption. Recall that the CV for the change in cigarette consumption  $A_{CF_t} - A_{R_t}$  is given by the area  $G + J + K$ . Ashley et al. (2014) refer to this as the net health benefits. As Cutler (2008) points out, with linear demand curves like in Figure 1, the area of the triangle  $G + J + K$  of net health benefits from this policy-induced change is exactly one-half the area

<sup>12</sup> Figure 1 assumes a perfectly elastic supply curve so there is no producer surplus.

<sup>13</sup> We would like to thank, without implicating, Amber Jessup and Martha Starr for their valuable insights about the relationship between agencies' public health missions and what we are terming the health benefits approach to BCA.

of the parallelogram  $E + F + I + G + J + K$  of gross health benefits. In other words, half of the gross health benefits are offset by lost consumer surplus. Ashley et al. (2014) emphasize that for other policy-induced changes and other assumptions the net-to-gross benefits or offset ratio can range from zero to 100%. Several recent RIAs of health-related regulations use offset ratios ranging from 10 to 99%.<sup>14</sup> The use of anything but a very small offset ratio near zero has been criticized in public comments on the RIAs, commentaries in public health journals and even in the popular press.<sup>15</sup>

Our market-based approach to the BCA of anti-smoking policies complements recent RIAs that use the health benefits approach. Our approach does not use estimates of the gross health benefits of anti-smoking policies, so it does not require an assumption about the appropriate offset ratio. Instead, as in the standard revealed preference approach to applied welfare economics, our approach analyses market behavior to infer the value of the policy-induced changes in cigarette consumption. Although it is not the main focus of our study, in Section 6 we return to a discussion of what our results imply for the health benefits approach to BCA and the consumer surplus offset controversy.

## 3 Retrospective analysis of the impact of U.S. anti-smoking policies 1964–2010

### 3.1 Background

The first step of our retrospective BCA is to define the set of anti-smoking policies and their impact on cigarette consumption. We consider the broad set of U.S.

---

<sup>14</sup> The offset ratio equals 1 minus the ratio of net-to-gross benefits discussed by Ashley et al. (2014). The evidence base of offset-ratio estimates is thin. Based on evidence from a contingent valuation study Weimer et al. (2009, p. 182) conclude that “between about 60 and 70% of the consumer surplus in the cigarette market should be counted as actual value for consumers.” This implies a nonzero offset ratio, but they cannot calculate an offset ratio because they do not compare consumer surplus to the gross health benefits. Ashley et al. (2014) use parameters from Gruber and Koszegi (2001) to develop estimates of the offset ratio ranging from about 67 to 99%. The RIA of cigarette graphic warning labels suggests an even wider range from 10 to 99% (FDA, 2011). For its primary calculations the FDA uses the midpoint of that range. The RIA of the tobacco product deeming regulation discusses offset ratios ranging from 67 to 84% (FDA, 2014a). The RIA of menu calorie labels uses the midpoint of 50% uniformly distributed between 10 and 90% (FDA, 2014b, p. 92).

<sup>15</sup> (FDA, 2011) summarizes the public comments received about the consumer surplus offset. Commentaries in public health journals criticizing the use offset include Song, Brown and Glantz (2014), Chaloupka et al. (2014, 2015). Popular press discussions include Tavernise (2014), New York Times Editorial Board (2014) and a Sunday Doonesbury comic strip by Garry Trudeau (September 14, 2014).

policies implemented over the period 1964–2010 that were designed to improve consumer information about the health consequences of cigarette smoking. As we mentioned above, the 1964 Surgeon General’s Report (SGR) is widely viewed as a landmark publication that launched modern anti-smoking policies in the United States. In its wake followed: additional SGRs further documenting the health consequences (almost annually); mandatory warning labels on cigarette packages and advertisements (enacted in 1965, strengthened in 1969, 1984, and pending); a ban on television and radio cigarette advertisements (1971); school-based health education about smoking (continuing); and mass media anti-smoking campaigns (continuing). School health education and mass media anti-smoking campaigns include new campaigns launched by state tobacco control programs in the 1990s and 2000s and the American Legacy Foundation’s ‘truth’ campaign funded by the 1998 Master Settlement Agreement between the tobacco industry and state attorneys general.

We do not attempt to isolate the impact of specific anti-smoking policies but instead consider their combined impact. Our approach is to attribute shifts in the observed cigarette demand curve  $D_{O_t}$  over time to the combined impact of anti-smoking information policies. Because we focus on shifts in demand that reflect improved consumer information, as explained below we control for movements along the demand curve caused by tax-induced changes in cigarette prices over time.

Conceptually, we view cigarette excise taxes as a policy tool to correct for negative externalities. Externalities in the cigarette market include the health and utility costs of nonsmokers’ exposure to second hand smoke and the financial costs smoking-related illnesses impose on nonsmokers in collectively financed health insurance and retirement plans. Empirically, Sloan, Ostermann, Picone, Conover and Taylor (2004, Table 11.3, p. 255) estimate that circa 2000 cigarette taxes were not high enough to fully correct for externalities: the estimated externality per pack of cigarettes is \$2.20 while the combined federal and average state cigarette tax per pack is \$0.76.<sup>16</sup> However, by the end of our study period in 2010 subsequent federal and state tax hikes raise the combined tax to \$2.18 per pack (Orzechowski & Walker, 2012). The externalities from second hand smoke are further corrected by the expansion of state and local bans on smoking in public places. From 2000–2009 the fraction of the U.S. population covered by smoke free worksite laws increased from 3% to 54% and the fraction covered by smoke free restaurant laws increased from 13% to 63% (Gonzalez, Sanders-Jackson, Song, Cheng & Glantz, 2013). Some of the financial externalities of smoking are further addressed by the 50%

<sup>16</sup> This updates the seminal study of the external costs of smoking by Manning, Keeler, Newhouse, Sloss and Wasserman (1991) and the later study by Viscusi (1995).

health insurance premium surcharges for smokers allowed under the 2010 Patient Protection and Affordable Care Act. The policy trends suggest that over the period we study: one set of anti-smoking policies helped correct individual failures; while another set of policies helped correct externalities. To focus on the benefits of correcting individual failures, our approach abstracts from the net benefits of tax and other policies that correct externalities.<sup>17</sup>

### 3.2 Dynamic population simulation model and data sources

We use a dynamic population model to compare observed cigarette consumption over time to cigarette consumption under a simulated “no-policy” counterfactual. Our simulation model is based on the model developed by Mendez, Warner and Courant (1998), which they use to accurately predict smoking prevalence through 2010 (Warner & Mendez, 2012). Our model begins with estimates of the adult population by smoking status in 1960. The model uses estimates of birth rates, smoking status-specific mortality rates, and age-specific smoking initiation and cessation rates to simulate the number of adults smoking over time. The smoking population evolves as new cohorts initiate smoking while current smokers either continue to smoke, quit smoking and become former smokers, or die. Aggregate cigarette consumption in year  $t$  is given by the size of the smoking population in year  $t$  multiplied by an estimate of the average number of cigarettes consumed per smoker in year  $t$ .

We use standard data on birth rates and estimates of mortality rates by smoking status from Jha et al. (2013). We follow Mendez et al. (1998) and assume that everyone aged 0–17 is a never-smoker, and some initiate smoking at age 18. We estimate sex-specific birth cohort smoking initiation rates from the Tobacco Use Supplements to the Current Population Survey (TUS-CPS). We also use these data to estimate sex- and age-specific smoking cessation rates. We use data on observed cigarette consumption from the *Tax Burden on Tobacco* (Orzechowski & Walker, 2012). An online Appendix provides more details about our simulation model and data sources.

It is useful to provide a brief overview of the trends in the input variables used in our dynamic population model. From 1964 to 2010 the adult population aged 18 and older grew from 120 to 205 million. The observed rate at which new

---

<sup>17</sup> This would be an interesting and worthwhile extension. Because the policies interact, the total of consumer benefits from the combination of informational and externality-correcting policies is not the simple sum of the benefits of the informational policies we consider and the externality-correcting policies we do not consider.

cohorts initiate smoking falls fairly steadily from 52% in 1964 to 17% in 2010. The observed average cessation rate increases from about 1.5% per year in 1964 to 3% in 1990 to almost 6% by 2010. The observed average number of cigarettes per smoker increases from 26.5 cigarettes per day in 1964 to a high of over 30 cigarettes per day in 1983. It then drops to 23 cigarettes per day by 2010. Using the observed initiation and cessation rates, the model's simulated smoking prevalence and cigarettes per day compare well to the observed (and incomplete) National Health Interview Survey and TUS-CPS data over this period.<sup>18</sup>


We create a no-policy counterfactual simulation to predict what cigarette consumption would have been in the absence of the 1964 SGR and subsequent anti-smoking policies. For the counterfactual we assume that smoking initiation and cessation rates are fixed at their 1964 levels. We assume that the counterfactual number of cigarettes per smoker increases as observed through 1983, and then remains constant at the 1983 level of over 30 cigarettes per day through 2010. To control for movements along the observed demand curve  $D_{CFi}$  due to price changes, we use price-elasticity to adjust for the differences in consumption due to the differences between  $P_{1964}$  and  $P_t$ .

The assumptions in the counterfactual simulations probably tend to overstate the impact of anti-smoking policies, for two reasons. First, even without the 1964 SGR and public informational campaigns, it is likely that consumers would naturally learn on their own about the medical research on the health risks of smoking.<sup>19</sup> If so, even without the policies smoking initiation rates would naturally fall and cessation rates would naturally rise. Second, the observed increase in the number of cigarettes per smoker from 1964 to 1983, which we assume would hold in the counterfactual, might not have occurred without the informational policies. Several econometric studies find that during this period smokers reacted to the new information about the health risks of smoking by switching to filter cigarettes and lower tar and lower nicotine cigarettes (Schneider, Klein & Murphy, 1981; Ippolito & Ippolito, 1984). If smokers compensated for these changes by smoking more, improved information paradoxically might explain the observed increase in the number of cigarettes per smoker.<sup>20</sup> The no-policy counterfactual should not include

<sup>18</sup> Detailed results are included in the online Appendix. We calculate the observed average number of cigarettes per smoker by dividing total U.S. consumption (from the *Tax Burden on Tobacco*) by the simulated number of smokers. As is well known, smokers under-report their daily consumption in surveys, but our estimates and estimates from self-reported data show the same pattern over time.

<sup>19</sup> Viscusi (1992, p. 35 and Tables 2–6) points out that there was substantial coverage of smoking risks in *Reader's Digest* during the 1950s, pre-dating the 1964 SGR and subsequent policies.

<sup>20</sup> Another possible explanation is that the observed increase in cigarettes per smoker reflects changes in the composition of the smoking population, if the consumers who would have been lighter smokers either never start smoking or are more likely to quit smoking.




**Figure 2** Retrospective impact analysis: counterfactual vs observed smoking prevalence.

any policy-induced increase in cigarettes per smoker, but we are unaware of data on this. Because these assumptions mean simulated counterfactual consumption is probably too high, our retrospective BCA can be seen as providing an upper bound estimate of the benefits of anti-smoking policies from 1964 to 2010.

### 3.3 Trends in actual and simulated counterfactual cigarette consumption

Figures 2 and 3 compare the observed trends in smoking prevalence and cigarette consumption from 1960 to 2010 to the results of the no-policy counterfactual simulation. Counterfactual smoking prevalence slightly declines from about 40% in 1960 to 37% in 2010. In the counterfactual case, the rates of smoking initiation and cessation are constant at their 1964 levels, so this slight drop in prevalence is due to changes in the age composition of the population. In contrast, observed smoking prevalence drops steadily and falls about in half to 17% in 2010. Due to population growth, from 1964 to about 1980 both counterfactual cigarette consumption and observed cigarette consumption increase. Counterfactual consumption continues to grow through 2010, but after 1980 the drop in observed smoking prevalence





**Figure 3** Retrospective impact analysis: counterfactual vs observed cigarette consumption.

(and after 1983 the drop in observed cigarettes per day) outweighs population growth, so observed consumption begins to fall. Observed consumption in 2010 is only 39% of the level predicted in the counterfactual simulation.

Observed cigarette consumption from 1964 to 2010 totals 1.13 trillion packs; under the no-policy counterfactual cigarette consumption totals 1.58 trillion packs over the same period. We use these simulation results to estimate that the overall impact of anti-smoking informational policies from 1964 to 2010 is to reduce cigarette consumption by 28%. This does not include reductions in cigarette consumption due to price increases over the period.

The policy-induced reductions grow over time, both in levels and in percentage terms. Observed consumption in 1974 is about 10% lower than counterfactual consumption. The reduction in observed consumption compared to counterfactual consumption grows to 21% in 1984 to 38% in 1994 to 48% in 2004 to 61% in 2010. The time pattern reflects wider dissemination of health information and the dynamics of the smoking population. Changes in the flows into and out of the smoking population due to changes in initiation and cessation are small relative to the stock of smokers. Their impact accumulates over time.

## 4 Retrospective BCA of anti-smoking policies 1964–2010

### 4.1 Constructing cigarette demand curves


To calculate the areas in Figure 1 that measure the consumer benefits of anti-smoking policies we construct a series of demand curves  $D_{CF}$ ,  $D_O$  and  $D_R | A_{t-1}$  for 1964–2010. The observed cigarette consumption levels and counterfactual simulation results provide points on the observed demand curves  $D_O$  and the counterfactual demand curves  $D_{CF}$ .

To find points on  $D_R | A_{t-1}$  we use our dynamic population model to simulate consumption over time based on the smoking rates of a group of consumers whose smoking behavior tends to approximate fully informed rational decision making. We use data from the 2011–2012 TUS-CPS on the distribution of various groups of consumers across smoking statuses. We restrict the sample to those aged 30–45 to focus on adult consumers who made the decision to start smoking well after the health consequences were widely publicized through the 1964 SGR and the anti-smoking campaigns that followed. We further restrict the sample to highly educated consumers to focus on consumers most able to align their behavior with their well-informed preferences. Based on the smoking behaviors by consumers in this group, in our simulations of the rational demand for cigarette consumption we assume: an initiation rate of 5%; the age- and sex-specific cessation rates of smokers in this highly educated group; and average consumption of 16 cigarettes per smoker per day.<sup>21</sup>

Figure 4 compares simulated rational cigarette consumption to observed consumption from 1964 to 2010. In 1964 rational consumption is estimated to be 18 billion packs, which is 79% of observed consumption in that year. Rational consumption is relatively constant over time. As noted above, observed consumption rises to a peak in the early 1980s and then steadily declines. In 2010 rational consumption is 11 billion packs, which is 72% of observed consumption.

A key feature of our approach is that the rational demand curve captures the linkages across time created by addiction. To find points on the rational demand curves  $D_{Rt} | A_{t-1}$  our simulation of rational consumption at time  $t$  reflects the addictive stock determined by observed consumption at time  $t - 1$ . As can be seen in Figure 4, persistence in the addictive stock means that the level of rational

<sup>21</sup> Our estimate of the number of cigarettes per day for rational smokers is based on 2010 TUS-CPS data on the number of cigarettes smoked per day self-reported by highly educated smokers, adjusted for under-reporting based on data on the total cigarette consumption.



Data source: Simulations using TUS-CPS.

**Figure 4** Retrospective BCA: rational vs observed cigarette consumption.

demand does not change quickly over time. The differences in the flows into and out of the smoking population due to differences in rational and observed initiation and cessation rates are small relative to the addictive stock. The large differences between rational and observed consumption that had started in 1964 and persisted over time are mainly driven by the differences in the rational and observed number of cigarettes smoked per day. Although our approach assumes that the size of the smoking population does not change quickly, we make the simplifying assumption that rational smokers would immediately cut their daily cigarette consumption. This assumption is driven in part by data limitations: research on nicotine withdrawal symptoms typically focuses on quit attempts, not on what happens when smokers cut down. Because our assumption overstates the difference between observed and rational demand, our approach tends to overstate the consumer benefits of anti-smoking policies.

To conduct our retrospective BCA we construct a series of demand curves  $D_O$ ,  $D_{CF}$ , and  $D_R | A_{t-1}$  over time. The observed market price and observed, simulated counterfactual, and simulated rational consumption at time  $t$  provide points on the respective demand curves at time  $t$ . Based on a consensus estimate that the price-elasticity of cigarette demand is  $-0.3$  (Gallet & List, 2003), we estimate a common

slope for the demand curves.<sup>22</sup> We then use the point-slope formula to construct a set of linear and parallel demand curves for the years 1964–2010.

Before turning to BCA results, we note an intermediate result from the constructed demand curves: a set of estimates of the vertical distances between the observed, counterfactual, and rational demand curves. These estimates are interesting in their own right because the vertical distances between  $D_{O_t}$  and  $D_{R_t} | A_{t-1}$  or  $D_{CF_t}$  and  $D_{R_t} | A_{t-1}$  measure the marginal internality, i.e., the health consequences of cigarette consumption that are uninternalized due to individual failures to optimize (see Figure 1). Based on the constructed demand curves, at the start of our study period in 1964 the marginal internality is \$1.07 per pack. By 2010 the marginal internality increases to \$3.61 per pack.<sup>23</sup> In terms of the graphed curves, at first the vertical distance between the other demand curves and  $D_{R_t} | A_{t-1}$  increases over time because  $D_{R_t} | A_{t-1}$  shifts inwards toward the origin more quickly. In terms of the economic forces at work, this pattern reflects the moving target nature of rational demand: as cigarette consumption falls over time, the reductions in the addictive stock reduce the level of rational consumption.

Our estimates of the marginal internality are much smaller than previous estimates of the average value of the health consequences per pack of cigarettes. Gruber and Koszegi (2001), Cutler (2002), Sloan et al. (2004) estimate that the average value of the health consequences of smoking is in the range of \$20–\$30 per pack; Viscusi and Hersch (2008) estimate that the average value is even higher at \$94 per pack for women and \$222 per pack for men. Analogous to the health benefits approach to BCA, these estimates are based on estimates of the lifetime health consequences of smoking combined with estimates of the dollar value of health. The lifetime value of the health consequences is then averaged over the lifetime number of packs. The lifetime average value is greater than the marginal internality in part because of the sunk cost nature of the addictive stock. In addition, the marginal internality reflects the impact of the anti-smoking policies that help correct for individual failures to internalize the health consequences of their cigarette consumption.<sup>24</sup>

<sup>22</sup> Based on the data used in most of the studies behind the consensus price-elasticity estimate we assume that  $-0.3$  is approximately the point-elasticity of the observed demand curve for cigarettes in 1984. This allows us to solve for the slope of  $D_{O,1984}$ . We then assume this slope is the same across the other demand curves.

<sup>23</sup> Complete results are available in the online Appendix. \$3.61 is the average of the marginal internality at  $A_{CF,2010}$  (\$6.25) and the marginal internality at  $A_{O,2010}$  (\$0.96). Put differently, \$3.61 is the average height of the area  $J + K$  in Figure 1.

<sup>24</sup> This can be seen in the trend in the marginal internality at  $A_{O_t}$  over time: the marginal internality declines from its peak of over \$2 per pack to \$0.96 per pack in 2010.

## 4.2 BCA of anti-smoking policies from 1964 to 2010

For each year from 1964 to 2010 we use the constructed demand curves  $D_{CF}$ ,  $D_O$  and  $D_R$  to calculate the CV measured by the area  $J + K$  in Figure 1. The sum of the CVs is our measure of the consumer benefits of the anti-smoking policies from 1964 to 2010.

At a discount rate of 3%, from the perspective of 1964 the present value of benefits of the anti-smoking policies is about \$573 billion (in 2010\$). At a discount rate of 7% the 1964–present value is \$191 billion. To provide some context for these large numbers: at a discount rate of 3% our estimate of the 1964–present value of benefits is actually larger than the 1964–present value of cigarette sales from 1964 to 2010. Another way to provide context is to calculate the benefits per smoker-year. Based on the present value of the number of smoker-years in the simulated no policy counterfactual, at a discount rate of 3% we estimate that the anti-smoking policies yield consumer benefits of \$369 per smoker-year.

We are unable to develop a hard estimate of the costs of anti-smoking policies from 1964 to 2010. The estimated consumer benefits flow from a broad set of federal, state, local and private-sector anti-smoking policies including: publication of SGRs and other government reports; mandatory warning labels; a ban of television and radio cigarette advertisements; school-based health education about smoking; and mass media anti-smoking campaigns. We were unable to find systematic data on the costs of these policies. Many of the informational policies involve fairly minor resource costs. The costs of school-based health education and mass media campaigns could be more substantial.

We use data on the costs of anti-smoking policies from 1985 to 2010 to make illustrative calculations of the costs over the full period 1964–2010. Starting in the late 1980s, states began to centralize their anti-smoking efforts in state tobacco control programs (Farrelly, Pechacek & Chaloupka, 2003). The 1998 Master Settlement Agreement between the tobacco industry and state attorneys general provided an additional stream of revenues for these programs and also funded the Legacy Foundation’s national “truth” mass media anti-smoking campaign. In our illustrative calculation we assume that from 1964–1998 the annual cost of anti-smoking policies equals the average program costs over the period 1985–1998. The admittedly loose justification is that prior to 1985 the costs of public sector anti-smoking policies might have been roughly comparable but were not centralized in specific state programs. This assumption probably overestimates the costs. For the years 1999–2010 we assume the annual cost of anti-smoking policies is given by the sum

of state tobacco control program expenditures and the expenditures of the Legacy Foundation.<sup>25</sup>

Based on those assumptions, our illustrative calculation is that at 3% discount rate the 1964–present value of costs is \$6.5 billion. At 7% the 1964–present value of costs is \$2.9 billion. Putting these cost estimates together with our estimates of the consumer benefits implies that anti-smoking policies from 1964 to 2010 yield net benefits of \$566 billion (at 3%) or \$188 billion (at 7%). Although the illustrative calculation is far from a hard estimate of the policy costs, the illustrative calculations suggest that the consumer benefits of the anti-smoking policies are likely to substantially outweigh the policy costs.

## 5 Prospective BCA of an anti-smoking policy from 2010 to 2040

Our prospective BCA estimates potential benefits from future FDA tobacco regulations. We use our dynamic population model to simulate a policy that: cuts the 2010 smoking initiation rate in half; increases the 2010 smoking cessation rates by a third; and decreases the 2010 number of cigarettes smoked per day by a third. The policy scenario and the rational scenario make the simplifying but unrealistic assumption that smokers immediately cut the number of cigarettes smoked per day, so both scenarios will overstate the reduction in consumption. The simulated levels of cigarette consumption under this policy scenario are approximately equal to the levels predicted under the rational scenario, so our prospective analysis corresponds to moving from  $A_{Ot}$  to  $A_{Rt}$  in Figure 1.

Given past reductions in cigarette consumption, the policy scenario we simulate is ambitious but perhaps attainable. The simulated changes in initiation, cessation, and cigarettes smoked per day are comparable in percentage terms to the changes observed over the past 15 years or so. While those reductions were achieved more gradually through policies such as mass media anti-smoking campaigns, future FDA tobacco regulations might change smoking behavior more quickly. Under the 2009 Tobacco Control Act, the FDA is required to enact new graphic warning labels and is allowed to make product changes such as banning menthol or reducing nicotine content. By changing important aspects of the smoking experience, these

---

<sup>25</sup> We do not use the 1999–2010 costs in the average cost we calculate because we assume expenditures during this period were higher than historically due to the special circumstances created by the 1998 Master Settlement Agreement.

regulations could lead to abrupt changes in initiation, cessation and cigarettes smoked per day.


Figures 5 and 6 show the predicted changes in smoking prevalence and aggregate cigarette consumption from the simulation model. As already noted, the policy scenario and the rational scenario simulations are approximately the same, so we only show the policy scenario. The status quo simulations predict trends in smoking prevalence and cigarette consumption if the rates of smoking initiation, cessation, and cigarettes smoked per day remain constant at their 2010 levels. The demographics of the smoking population imply that even at current rates of initiation and cessation smoking prevalence is predicted to drop from 20% in 2010 to 14% in 2020, 11% in 2030, and 9% in 2040.<sup>26</sup> Under the policy scenario, smoking prevalence drops more: to 12% in 2020, 7% in 2030, and 5% in 2040. Due to our assumption about the drop in cigarettes smoked per day, from 2010 to 2011 cigarette consumption falls immediately by one third. After 2011, cigarette consumption continues to decline slowly at first and then more rapidly due to the predicted drop in smoking prevalence. By 2040 under the simulated policy scenario, cigarette consumption is about one third the level predicted for 2040 under the status quo simulation.

Figures 5 and 6 provide another illustration of the importance of the addictive stock and the moving target nature of rational demand. Given the addictive stock smokers in 2010 inherit due to their past consumption decisions, for the first few years simulated rational smoking prevalence is very close to status quo smoking prevalence.

To estimate the benefits of the simulated policy we use the status quo simulation to construct a series of observed demand curves  $D_{O_t}$  and the policy simulations to construct a series of rational demand curves  $D_{R_t} | A_{t-1}$ . We then calculate the area  $G$  of consumer benefits from reducing  $Q_{O_t}$  to  $Q_{R_t}$  (see Figure 1). At a discount rate of 3% the 2010–present value of the consumer benefits from the simulated FDA tobacco regulation through 2040 is estimated to be \$100 billion. At a discount rate of 7% the present value of the simulated regulation is \$65 billion.

Compared to the consumer benefits, the direct resource costs of future FDA tobacco regulation are likely to be low. For example, the FDA (2011) estimates that the discounted present value of the costs of implementing and enforcing the

<sup>26</sup> This updates earlier predictions from the Mendez et al. (1998) simulation model that: “the demographics of smoking imply that prevalence will inexorably continue to decline over the next several decades, even without any intensified efforts aimed at tobacco control.” The simulations accurately track observed smoking prevalence through 2010 (Warner & Mendez, 2012). The reductions in future smoking prevalence and cigarette consumption in our simulation flow from past reductions in smoking initiation and increases in smoking cessation. Because these reductions, in turn, flow from past anti-smoking policies, our status quo simulation implies that past anti-smoking policies will provide a stream of additional benefits through 2040.



Data source: simulations.

**Figure 5** Prospective BCA: smoking prevalence rates.


proposed graphic warning labels is \$434 million (3% discount rate) and \$392 million (7% discount rate). These estimates of implementation and enforcement costs are less than 1% of our estimates of the consumer benefits from the simulated FDA tobacco regulation. However, future FDA regulations that require product changes such as very low-nicotine content might be more costly to implement and enforce than graphic warning labels, especially in the short-run.<sup>27</sup>

The nature of future FDA regulations implies that it might also be important to consider additional costs related to consumer losses in utility. In the conceptual framework above these losses correspond to the utility losses from changes in cigarette quality ( $\Delta G$ ).<sup>28</sup> Changes in cigarette quality should be thought of broadly and include changes in flavor, changes in nicotine levels, and changes in other

<sup>27</sup> The 22nd Century Group produces very low-nicotine Spectrum brand cigarettes from genetically modified tobacco plants and provides them to researchers. To meet the demand created by an FDA regulation that substantially lowers nicotine levels, tobacco growers would need to shift from conventional tobacco plants to the new genetically modified plants. Cigarette manufacturers might also try to reformulate cigarettes to offset possible changes in the perceived taste of the very low-nicotine cigarettes. The reformulations would also be subject to FDA regulations, further increasing enforcement costs.

<sup>28</sup> In terms of Figure 1, the decrease in quality shifts the rational demand curve inwards. If Figure 1 is extended this way, the area between  $D_R$  | initial quality and  $D_R$  | lower quality captures the consumer welfare loss from the quality decrease ( $\Delta G$ ).





Data source: simulations.

**Figure 6** Prospective BCA: cigarette consumption.

aspects of the smoking experience. For example, the experimental study used to develop and test the proposed graphic warning labels finds that exposure to the images on most of the labels elicited strong emotional responses including feeling “disgusted or grossed out” and that “the pack is difficult to look at.”<sup>29</sup> A complete estimate of the costs of graphic warning labels needs to include the dollar value of the corresponding utility losses from the changed smoking experience. To illustrate the potential magnitude of the utility losses: if product changes or graphic labels reduce the value of cigarettes to consumers by \$1 per pack, the discounted present value of the utility losses through 2040 is \$163 billion at a discount rate of 3% and \$118 billion at a discount rate of 7%.<sup>30</sup> Utility losses of this magnitude would mean that the simulated FDA regulation would fail to meet the benefit-cost test.

<sup>29</sup> See Nonnemaker, Farrelly, Kamyab, Busey and Mann (2010). They note (page 4-2) evidence from other studies that “images that evoke the strongest graphic or emotional responses are likely to be the most effective. . . .” However, their experimental results provides relatively weak evidence that the studied labels increase risk awareness or were effective in encouraging cessation or discouraging initiation.

<sup>30</sup> Although \$1 per pack is only used for an illustrative estimate, it might be in the right ball park. The cigarette market includes several quality tiers that vary substantially in price. By revealed preference, smokers of premium brands are willing to pay more for the combination of better taste and other

## 6 Discussion

We implement a market-based behavioral economics approach to conduct retrospective and prospective BCAs of U.S. anti-smoking policies. Our retrospective BCA finds that the reduction in cigarette consumption from anti-smoking policies from 1964 to 2010 yields substantial consumer benefits that are likely to far exceed the policies' costs. Our prospective BCA shows that future FDA regulations can yield additional consumer benefits, but the estimated consumer benefits from future regulations are smaller than the benefits from past anti-smoking policies. The nature of some potential future FDA regulations also makes it less clear that their net benefits will be positive.

Like any BCA, our analysis involves a number of simplifying assumptions and faces data limitations. For reasons we have explained above, some key simplifying assumptions mean that the counterfactual simulations probably overstate the impact of the anti-smoking policies in both the retrospective and prospective analyses. Our estimates might be seen as upper bounds of the consumer benefits from the policies. However, the net impact of assumptions about the cigarette demand functions (slopes and functional forms) is harder to judge.<sup>31</sup> The potential sensitivity of the results to these assumptions reflects the difficulty of using observed consumption to extrapolate counterfactual consumption. Despite these limitations, we believe that our analysis provides a useful worked example of behavioral BCA of a major area of public health policy.

A useful direction for future work is to extend our aggregate analysis to incorporate individual-level heterogeneity in the demand for cigarettes. If peer effects and the perceived value of the health risks of smoking vary over the life cycle, age will be an important source of heterogeneity in cigarette demand. Income is another important source of heterogeneity in the value of health risks (Kniesner, Viscusi & Ziliak, 2010). Because higher income consumers place a higher value on health

---

perceived attributes of premium brands over lower price alternatives. In data from the New York Adult Tobacco Survey from 2003 to 2007, the average price of premium cigarettes was \$4.70 per pack, compared to \$3.50 per pack for discount brands and \$2.60 per pack for generic brands (DeCicca, Kenkel & Liu, 2015). That is, on average smokers of premium brands are willing to pay at least \$1.20 more than for discounts and at least \$2.10 more than for generics. In this context, it seems reasonable to suggest that major regulation-induced changes in cigarette attributes might be valued at -\$1 per pack.

**31** To begin to explore this, instead of assuming that the price-elasticity of demand is  $-0.3$  we have varied it from  $-0.15$  to  $-0.45$ . In our retrospective BCA, at a discount rate of 3% the 1964–present value of benefits ranges from \$382 billion (if the price-elasticity is  $-0.45$ ) to \$1.1 trillion (if the price-elasticity is  $-0.15$ ). In our prospective BCA, at a discount rate of 3% the present value of benefits ranges from \$66 billion (if the price-elasticity is  $-0.45$ ) to \$199 billion (if the price-elasticity is  $-0.15$ ).

risks their cigarette demand will be lower.<sup>32</sup> In a BCA heterogeneity in cigarette demand will translate into heterogeneity in consumer benefits from anti-smoking policies. Our estimates of the aggregate benefits of retrospective and prospective anti-smoking policies might mask important differences in the benefits across sub-groups. For example, estimating the benefits and costs of FDA tobacco regulations for low-income consumers parallels the question of the regressivity of cigarette excise taxes (Colman & Remler, 2008).

Our market-based approach complements the health benefits approach used in recent BCAs/RIAs of health-related FDA regulations. To measure consumer net benefits from anti-smoking policies we analyze observed choices in the market for cigarettes and make adjustments to reflect individual failures to make utility-maximizing decisions. The health benefits approach instead focuses on the gross value of the health benefits and then adjusts for consumer surplus losses. Although it is not our main focus or approach in this analysis, an illustrative extension of our simulation model yields estimates of the number of lives saved by anti-smoking policies in our retrospective and prospective analyses. Using a value of statistical life of \$7 million, we estimate that at a discount rate of 3% the 1964–present value of the gross life-saving benefits of anti-smoking policies from 1964 to 2010 is about \$8.8 trillion. At the same discount rate, our market-based approach provides an estimate that the net consumer benefits of the policies is \$573 billion. Putting together these estimates, which we reemphasize are from quite different approaches, implies that net benefits are only about 6% of the gross health benefits. About 94% of the gross health benefits from past anti-smoking policies are offset by losses of consumer surplus in the cigarette market. In the prospective analysis, the calculations imply that about 33% of the gross health benefits from hypothetical FDA regulations are offset by losses of consumer surplus from the reduced consumption of cigarettes.

Our illustrative calculations are consistent with the higher end of the range of consumer surplus offset ratios discussed in recent RIAs that use the health benefits approach to conduct BCAs of health-related regulations. In contrast, some critics of these RIAs argue that the offset ratio should be very small or zero. An offset ratio of zero is inconsistent with the compensation variation (CV) measure of consumer welfare in both standard and behavioral welfare economics. From the definition of the CV in equation (1) above, the gross value of the health improvements (the dollar value of  $\Delta H$ ) is an incomplete benefits measure that neglects the value of other important determinants of consumer welfare ( $\Delta A$ ,  $\Delta G$ , and  $\Delta Y$ ). The consumer

---

<sup>32</sup> This might be part of the reason highly educated consumers smoke less. If so, this provides another caveat to our assumption that other groups' rational demand can be approximated by the demand by highly educated.

surplus offset is a standard measure of the value of the policy-induced changes in cigarette consumption ( $\Delta A$ ) net of the value of changes in consumption of other goods ( $\Delta Y$ ). FDA regulations that affect cigarette attributes such as menthol flavoring or nicotine content might result in additional losses in utility ( $\Delta G$ ); methods to measure these losses deserve more attention.<sup>33</sup> At least some of the critics of the consumer offset implicitly or explicitly reject the usefulness of the economic approach and BCA. Many of these critics neither offer an alternative approach to BCA nor seem to think that an alternative approach is needed. Instead, they see the public health gains as sufficient justification for new anti-smoking regulations.<sup>34</sup>

Other critics argue that the offset ratio should be very close to zero based on what they refer to as “the principle of reason” (Chaloupka, Gruber & Warner 2015). They suggest that legal purchase age laws mean that “society has clearly decided that the decision to initiate smoking is an irrational decision and any changes in their conventionally calculated consumer surplus...should not be counted...” (p. 5). They conclude that “the vast majority of any consumer surplus loss should be ignored given that most tobacco users become addicted regular users before reaching the legal purchase age” (p. 6). Our approach is partly consistent with their principle of reason. Our simulations of the rational demand for cigarettes modify conventional calculations to incorporate the assumption that most smoking initiation decisions are irrational.<sup>35</sup> However, in our simulations rational demand at time  $t$  reflects the addictive stock from past consumption decisions regardless of whether the past decisions were rational. We suggest that the value of avoiding the symptoms of cigarette withdrawal might be the major determinant of demand by currently rational cigarette addicts. In contrast to the approach suggested by Chaloupka et al. (2014), our approach gives full standing in the BCA to the cigarette withdrawal costs and other utility losses by cigarette consumers.

We hope that worked examples including this study will help further develop the methods for behavioral BCA that retain the strong conceptual framework and rigor of BCA. Although the idea that addiction is a special case has an intuitive appeal, Bernheim and Rangel (2005, p. 3) stress the need for a unified framework

---

33 The FDA (2011, 2014b,a) RIAs do not include these losses when calculating their suggested offset ratios.

34 For example, Song et al. (2014) argue that: “Continued application of a consumer surplus discount will undermine sensible policies to reduce tobacco use and other policies to promote public health.” This argument begs the question, in the logician’s sense of assuming the conclusion, of the BCA: are the proposed policies indeed “sensible”?

35 In our rational demand simulations we assume that the rational initiation rate is 5%. Based on a 2002 survey finding that 91.2% of smokers state they never would have started smoking if they had to do it all over again, Chaloupka et al. (p. 5) suggest that perhaps the remaining 8.8% of smokers made rational initiation decisions. In 2002 smoking prevalence is about 23%, so their suggestion implies the rational initiation rate is around 2%.

for behavioral welfare economics: “If we can classify, say, the consumption of an addictive substance as contrary to an individual’s interests, what about choices involving literature, religion, or sexual orientation?” Our behavioral BCA applies an approach based on a unified framework to anti-smoking policies.

The net benefits criterion is not, and in our view should not be, the sole criterion used to evaluate public policies. The BCAs required by the RIA process inform and improve but do not always dictate federal regulations. It is natural and appropriate that federal agencies with public health missions are informed by public health ethics. For example, Jones and Bayer (2007) argue that many public health policies are “justified paternalism” and urge public health officials to recognize (p. 216) that “paternalistic protective legislation is part of the warp and woof of public health practice in America.” Policies justified by paternalism might not meet the net benefits criterion, and vice versa. There is no need to modify the BCA framework to guarantee that it reaches the same conclusions as other normative criteria.

## Supplementary material

To view supplementary material for this article, please visit <http://dx.doi.org/10.1017/bca.2014.1>.

## References

- Ashley, E. M., Nardinelli, C. & Lavaty, R. A. (2014). Estimating the Benefits of Public Health Policies That Reduce Harmful Consumption. *Health Economics*, 25, 10.
- Australian Productivity Commission (2010). Gambling, Report no. 50, Canberra.
- Bernheim, B. Douglas & Rangel, Antonio (2005). *Behavioral Public Economics: Welfare and Policy Analysis with Non-standard Decision Makers*. National Bureau of Economic Research. Working Paper 11518.
- Bernheim, B. Douglas & Rangel, Antonio (2007). Toward Choice-Theoretic Foundations for Behavioral Welfare Economics. *American Economic Review*, 97(2), 464–470.
- Bernheim, B. Douglas & Rangel, Antonio (2009). Beyond Revealed Preference: Choice-Theoretic Foundations for Behavioral Welfare Economics. *Quarterly Journal of Economics*, 124(1), 51–104.
- Bureau of Economic Analysis (2015). Table of “Current-dollar and ‘Real’ GDP.” Statistical Tables Relating to Income, Employment, and Production. Table B - 1 Appendix B. [http://www.whitehouse.gov/sites/default/files/docs/erp2013/ERP2013\\_Appendix\\_B.pdf](http://www.whitehouse.gov/sites/default/files/docs/erp2013/ERP2013_Appendix_B.pdf).
- Busch, S. H., Falba, T. A., Duchovny, N., Jofre-Bonet, M., O’Malley, S. S. & Sindelar, J. L. (2004). Value to Smokers of Improved Cessation Products: Evidence from a Willingness-to-Pay Survey. *Nicotine & Tobacco Research*, 6(4), 631–639.

- Carson, Richard T. (2012). Contingent Valuation: A Practical Alternative when Prices Aren't Available. *Journal of Economic Perspectives*, 26(4), 27–42.
- Chaloupka, Frank J., Gruber, Jonathan & Warner, Kenneth E. (2015). Accounting for “Lost Pleasure” in a Cost–Benefit Analysis of Government Regulation: The Case of the FDA’s Proposed Cigarette Labeling Regulation. *Annals of Intern Medicine*, 162(1), 64.
- Chaloupka, F. J., Warner, K. E., Acemoglu, D., Gruber, J., Laux, F., Max, W., Newhouse, J., Schelling, T. & Sindelar, J. (2014). An Evaluation of the FDA’s Analysis of the Costs and Benefits of the Graphic Warning Label Regulation. *Tobacco Control*, 30, 052022.
- Chetty, Raj (2009). Sufficient Statistics for Welfare Analysis: A Bridge Between Structural and Reduced-Form Methods. *Annual Review of Economics*, 1, 451–487.
- Colman, Gregory J. & Remler, Dahlia K. (2008). Vertical Equity Consequences of Very High Cigarette Tax Increases: If the Poor are the Ones Smoking, How Could Cigarette Tax Increases be Progressive? *Journal of Policy Analysis and Management*, 27(2), 376–400.
- Cutler, David M. (2002). Health Care and the Public Sector. In Alan J. Auerbach & Feldstein Martin (Eds.), *Handbook of Public Economics* (pp. 2145–2243). North Holland: Elsevier Science.
- Cutler, David M. (2008). Are We Finally Winning the War on Cancer? *Journal of Economic Perspectives*, 22(4), 3–26.
- Deaton, Angus & Muellbauer, John (1980). *Economics and Consumer Behavior*. Cambridge: Cambridge University Press.
- DeCicca, Philip, Kenkel, Donald & Liu, Feng (2015). Reservation Prices: An Economic Analysis of Cigarette Purchases on Indian Reservations. *National Tax Journal*, 68(1), 93–118.
- DellaVigna, Stefano (2009). Psychology and Economics: Evidence from the Field. *Journal of Economic Literature*, 47(2), 315–372.
- Farrelly, Matthew C., Pechacek, Terry F. & Chaloupka, Frank J. (2003). The Impact of Tobacco Control Program Expenditures on Aggregate Cigarette Sales: 1981–2000. *Journal of Health Economics*, 22(5), 843–859.
- Food and Drug Administration (2010). *Required Warnings for Cigarette Packages and Advertisements, Proposed Rule*. Federal Register 75: 69524–65.
- Food and Drug Administration (2011). *Required Warnings for Cigarette Packages and Advertisements, Final Rule*. Federal Register 76: 36628–777.
- Food and Drug Administration. (2014a). *Deeming Tobacco Products to be Subject to the Federal Food, Drug and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act*. Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, Proposed Rule. Federal Register 79: 23142–207.
- Food and Drug Administration (2014b). *Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments*. Final Regulatory Impact Analysis. FDA-2011-F-0172. Office of Regulations, Policy, and Social Sciences. Center for Food Safety and Applied Nutrition.
- Gallet, Craig A. & List, John A. (2003). Cigarette Demand: A Meta-Analysis of Elasticities. *Health Economics*, 12(10), 821–835.
- Gallup (1960). Gallup Poll, May 1960, #628.
- Gayer, Ted & Viscusi, W. Kip (2013). Overriding Consumer Preferences with Energy Regulations. *Journal of Regulatory Economics*, 43(3), 248–264.
- Gine, Xavier, Karlan, Dean & Zinman, Jonathan (2010). Put Your Money Where Your Butt Is: A Commitment Contract for Smoking Cessation. *American Economic Journal-Applied Economics*, 2(4), 213–235.

- Gonzalez, Mariaelena, Sanders-Jackson, Ashley, Song, Anna V., Cheng, Kaiwen & Glantz, Stanton A. (2013). Strong Smoke-Free Law Coverage in the United States by Race/Ethnicity: 2000–2009. *American Journal of Public Health*, 103(5), e62–e66.
- Gruber, Jonathan & Koszegi, B. (2001). Is Addiction Rational? Theory and Evidence. *Quarterly Journal of Economics*, 116(4), 1261–1303.
- Hammar, H. & Johansson-Stenman, O. (2004). The Value of Risk-free Cigarettes—Do Smokers Underestimate the Risk? *Health Economics*, 13(1), 59–71.
- Harberger, Arnold C. (1971). Three Basic Postulates for Applied Welfare Economics: An Interpretive Essay. *Journal of Economic Literature*, 9(3), 785–797.
- Hausman, Jerry (2012). Contingent Valuation: From Dubious to Hopeless. *Journal of Economic Perspectives*, 26(4), 43–56.
- Hughes, J. R. (2007). Effects of Abstinence from Tobacco: Valid Symptoms and Time Course. *Nicotine Tob Res*, 9(3), 315–327.
- Hughes, J. R., Keely, J. & Naud, S. (2004). Shape of the Relapse Curve and Long-term Abstinence among Untreated Smokers. *Addiction*, 99(1), 29–38.
- Ippolito, Pauline M. & Ippolito, Richard A. (1984). Measuring the Value of Life Saving from Consumer Reactions to New Information. *Journal of Public Economics*, 31, 53–81.
- Jha, Prabhat, Landsman, Victoria, Rostron, Brian, Thun, Michael, Anderson, Robert N., McAfee, Tim & Peto, Richard (2013). 21st-Century Hazards of Smoking and Benefits of Cessation in the United States. *New England Journal of Medicine*, 368(4), 341–350.
- Jones, Marian Moser & Bayer, Ronald (2007). Paternalism and Its Discontents—Motorcycle Helmet Laws, Libertarian Values, and Public Health. *American Journal of Public Health*, 97(2), 208–217.
- Kahneman, D., Wakker, P. P. & Sarin, R. (1997). Back to Bentham?—Explorations of Experienced Utility. *Quarterly Journal of Economics*, 112(2), 375–405.
- Kenkel, Donald S. & Chen, Likwang (2000). Consumer Information and Tobacco Use. In P. Jha & F. J. Chaloupka (Eds.), *Tobacco Control in Developing Countries* (pp. 177–214). Oxford University Press.
- Khwaja, Ahmed, Silverman, Dan & Sloan, Frank (2007). Time Preference, Time Discounting, and Smoking Decisions. *Journal of Health Economics*, 26(5), 927–949.
- Khwaja, Ahmed, Silverman, Dan, Sloan, Frank & Wang, Yang (2009). Are Mature Smokers Misinformed? *Journal of Health Economics*, 28(2), 385–397.
- King, Brian A., Dube, Shanta R. & Tynan, Michael A. (2012). Current Tobacco Use Among Adults in the United States: Findings from the National Adult Tobacco Survey. *American Journal of Public Health*, 102(11), e93–e100.
- Kling, Catherine L., Phaneuf, Daniel J. & Zhao, Jinhua (2012). From Exxon to BP: Has Some Number Become Better than No Number? *Journal of Economic Perspectives*, 26(4), 3–26.
- Kniesner, Thomas J., Viscusi, W. Kip & Ziliak, James P. (2010). Policy Relevant Heterogeneity in the Value of Statistical Life: New Evidence from Panel Data Quantile Regressions. *Journal of Risk and Uncertainty*, 40, 15–31.
- Manning, Willard G., Keeler, Emmett B., Newhouse, Joseph P., Sloss, Elizabeth M. & Wasserman, Jeffrey (1991). *The Costs of Poor Health Habits*. Cambridge, MA: Harvard University Press.
- Mendez, David, Warner, Kenneth E. & Courant, Paul N. (1998). Has Smoking Cessation Ceased? Expected Trends in the Prevalence of Smoking in the United States. *American Journal of Epidemiology*, 148(3), 249–258.



- Mokdad, A. H., Marks, J. S., Stroup, D. F. & Gerberding, J. L. (2004). Actual Causes of Death in the United States, 2000. *JAMA—Journal of the American Medical Association*, 291(10), 1238–1245.
- Mullainathan, Sendhil, Schwartzstein, Joshua & Congdon, William J. (2012). A Reduced-Form Approach to Behavioral Public Finance. *Annual Review of Economics*, 4(4), 511–540.
- New York Times Editorial Board (2014). A Misguided Tobacco Proposal. *New York Times*, August 8, 2014.
- Nonnemaker, James, Farrelly, Matthew, Kamyab, Kian, Busey, Andrew & Mann, Nathan (2010). *Experimental Study of Graphic Cigarette Warning Labels*. rti International. Final Report prepared for Center for Tobacco Products, FDA.
- Office of Management and the Budget (2011). *Regulatory Impact Analysis: A Primer*.
- Orzechowski & Walker (2012). *The Tax Burden on Tobacco: Historical Compilation* (Vol. 47) Retrieved November 1, 2014, from [http://www.taxadmin.org/fta/tobacco/papers/tax\\_burden.2012.pdf](http://www.taxadmin.org/fta/tobacco/papers/tax_burden.2012.pdf).
- Robinson, Lisa A. & Hammitt, James K. (2011). Behavioral Economics and the Conduct of Benefit-Cost Analysis: Towards Principles and Standards. *Journal of Benefit-Cost Analysis*, 2(2), Article 5.
- Schneider, Lynne, Klein, Benjamin & Murphy, Kevin M. (1981). Government Regulation of Cigarette Health Information. *Journal of Law and Economics*, 24, 575–612.
- Sloan, Frank A., Ostermann, Jan, Picone, Gabriel, Conover, Christopher & Taylor, Donald H., Jr. (2004). *The Price of Smoking*. Cambridge, MA: The MIT Press.
- Sloan, Frank & Platt, Alyssa (2011). Information, Risk Perceptions, and Smoking Choices of Youth. *Journal of Risk and Uncertainty*, 42(2), 161–193.
- Sloan, Frank A. & Wang, Yang (2008). Economic Theory and Evidence on Smoking Behavior of Adults. *Addiction*, 103(11), 1777–1785.
- Song, Anna V., Brown, Paul & Glantz, Stanton A. (2014). When Health Policy and Empirical Evidence Collide: The Case of Cigarette Package Warning Labels and Economic Consumer Surplus. *American Journal of Public Health*, 104(2), E42–E51.
- Tavernise, Sabrina (2014). In New Calculus on Smoking, It's Health Gained vs. Pleasure Lost. *New York Times*, August 6, 2014.
- Thaler, Richard H. & Cass R., Sunstein (2009). *Nudge: Improving Decisions about Health, In Wealth, and Happiness*. London: Penguin Books.
- U.S. Government Publishing Office (2015). Budget of the United States Government. Table 3.2—Outlays by Function and Subfunction: 1962–2019.
- Viscusi, W. K. (1990). Do Smokers Underestimate Risks. *Journal of Political Economy*, 98(6), 1253–1269.
- Viscusi, W. K. (1991). Age Variations in Risk Perceptions and Smoking Decisions. *Review of Economics and Statistics*, 73(4), 577–588.
- Viscusi, W. Kip (1992). *Smoking: Making the Risky Decision*. New York: Oxford University Press.
- Viscusi, W. Kip (1995). Cigarette Taxation and the Social Consequences of Smoking. In James Poterba (Ed.), *Tax Policy and the Economy* (pp. 51–102). MIT Press.
- Viscusi, W. Kip & Hersch, Joni (2008). The Mortality Cost to Smokers. *Journal of Health Economics*, 27(4), 943–958.
- Warner, Kenneth E. (2007). Charting the Science of the Future Where Tobacco-Control Research Must Go. *American Journal of Preventive Medicine*, 33(6), S314–S317.



- Warner, Kenneth E. & Mendez, David (2012). Accuracy and Importance of Projections From a Dynamic Simulation Model of Smoking Prevalence in the United States. *American Journal of Public Health*, 102(11), 2045–2048.
- Weimer, David L., Vining, Aidan R. & Thomas, Randall K. (2009). Cost-Benefit Analysis Involving Addictive Goods: Contingent Valuation to Estimate Willingness-to-Pay for Smoking Cessation. *Health Economics*, 18(2), 181–202.